Oncology biotech Revolution Medicines sets terms for $150 million IPO

Revolution Medicines, a Phase 1/2 biotech developing targeted cancer therapies using the RAS pathway, announced terms for its IPO on Monday.

The Redwood City, CA-based company plans to raise $150 million by offering 10 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Revolution Medicines would command a fully diluted market value of $850 million.